Literature DB >> 19806251

Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: A focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP).

Beate Luxembourg1, Joern Schmitt, Marek Humpich, Matthias Glowatzki, Dejan Dressler, Erhard Seifried, Edelgard Lindhoff-Last.   

Abstract

There have recently been reports of an increased incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism (VTE) compared to patients with risk-associated VTE. The aim of our study was to evaluate whether elevated clotting factors, which have been linked to chronic sub-clinical inflammation and arterial thromboembolic disease, have a higher prevalence in idiopathic VTE compared to secondary VTE. Plasma fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP) levels were determined in a cohort of sex- and age-matched patients with unprovoked VTE (n=101), patients with secondary VTE (n=101), and controls (n=202). Fibrinogen and hs-CRP levels were higher in patients with idiopathic VTE (fibrinogen: median/range: 331/214-524 mg/dl; hs-CRP: median/interquartile range: 1.8/0.8-3.7 mg/l) than in those with risk-associated VTE (299/162-458 mg/dl, p=0.004; 1.5/0.8-2.2 mg/l, p=0.05) and controls (302/185-644 mg/dl, p=0.001; 1.2/0.5-2.2 mg/l, p=0.02). Fibrinogen levels in the upper tertile of the controls were seen in 53% of patients with unprovoked VTE, compared to 35% of patients with secondary VTE. According to their hs-CRP levels (>3 mg/l), 26% of patients with idiopathic VTE were categorised as being at high risk for cardiovascular disease, as opposed to just 9% of those with risk-associated VTE. Factor VIII activity was significantly higher in patients with both idiopathic and secondary VTE than in controls, with the highest median value in patients with idiopathic VTE. Our data show that markers of inflammation, such as hs-CRP, fibrinogen, and factor VIII, are at higher levels in patients with idiopathic compared to secondary VTE, supporting the hypothesis that idiopathic VTE and arterial thromboembolism share common risk factors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19806251     DOI: 10.1160/TH-09-02-0104

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

1.  Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia.

Authors:  Margaret V Ragni; Rachel C Jankowitz; Kristen Jaworski; Elizabeth P Merricks; Mark T Kloos; Timothy C Nichols
Journal:  Thromb Haemost       Date:  2011-08-11       Impact factor: 5.249

2.  Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A.

Authors:  Margaret V Ragni; Enrico M Novelli; Anila Murshed; Elizabeth P Merricks; Mark T Kloos; Timothy C Nichols
Journal:  Thromb Haemost       Date:  2012-12-13       Impact factor: 5.249

3.  Mechanisms and mitigating factors for venous thromboembolism in chronic kidney disease: the REGARDS study.

Authors:  K L Cheung; N A Zakai; P W Callas; G Howard; B K Mahmoodi; C A Peralta; S E Judd; M Kurella Tamura; M Cushman
Journal:  J Thromb Haemost       Date:  2018-08-09       Impact factor: 5.824

4.  Factor VIII concentration is greater in female than male patients with HIV infection.

Authors:  Alireza Abdollahi; Afsaneh Morteza; Omid Khalilzadeh; Ahmad Ahmadzadeh
Journal:  Int J Hematol       Date:  2010-12-15       Impact factor: 2.490

5.  Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.

Authors:  Seoyoung C Kim; Daniel H Solomon; Jun Liu; Jessica M Franklin; Robert J Glynn; Sebastian Schneeweiss
Journal:  Am J Med       Date:  2014-12-20       Impact factor: 4.965

6.  High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism: the Tromso study.

Authors:  Erin M Hald; Sigrid K Brækkan; Ellisiv B Mathiesen; Inger Njølstad; Tom Wilsgaard; Jan Brox; John-Bjarne Hansen
Journal:  Haematologica       Date:  2011-04-20       Impact factor: 9.941

7.  Risk of venous thromboembolism in patients with rheumatoid arthritis.

Authors:  Seoyoung C Kim; Sebastian Schneeweiss; Jun Liu; Daniel H Solomon
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-10       Impact factor: 4.794

8.  Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice.

Authors:  Kellie R Machlus; Feng-Chang Lin; Alisa S Wolberg
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

Review 9.  Diet as prophylaxis and treatment for venous thromboembolism?

Authors:  David K Cundiff; Paul S Agutter; P Colm Malone; John C Pezzullo
Journal:  Theor Biol Med Model       Date:  2010-08-11       Impact factor: 2.432

Review 10.  Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review.

Authors:  Francisco Galeano-Valle; Lucía Ordieres-Ortega; Crhistian Mario Oblitas; Jorge Del-Toro-Cervera; Luis Alvarez-Sala-Walther; Pablo Demelo-Rodríguez
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.